GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » ROC (Joel Greenblatt) %

CNBX Pharmaceuticals (CNBX Pharmaceuticals) ROC (Joel Greenblatt) % : -349.15% (As of Feb. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CNBX Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -349.15%.

The historical rank and industry rank for CNBX Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

CNBX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -26900   Med: -927.5   Max: 112.95
Current: -1110.76

During the past 13 years, CNBX Pharmaceuticals's highest ROC (Joel Greenblatt) % was 112.95%. The lowest was -26900.00%. And the median was -927.50%.

CNBX's ROC (Joel Greenblatt) % is ranked worse than
68.79% of 1461 companies
in the Biotechnology industry
Industry Median: -318.79 vs CNBX: -1110.76

CNBX Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


CNBX Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for CNBX Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals ROC (Joel Greenblatt) % Chart

CNBX Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 112.95 -774.16 -423.90 -813.15 -1,041.85

CNBX Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -267.74 -207.81 -3,998.64 -269.28 -349.15

Competitive Comparison of CNBX Pharmaceuticals's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, CNBX Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's ROC (Joel Greenblatt) % falls into.



CNBX Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Nov. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + -2.7755575615629E-17) - (1.168 + 0 + 0)
=-1.168

Working Capital(Q: Feb. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (1.23 + 0 + -0.00099999999999989)
=-1.229

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of CNBX Pharmaceuticals for the quarter that ended in Feb. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Feb. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2023  Q: Feb. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.824/( ( (0.236 + max(-1.168, 0)) + (0 + max(-1.229, 0)) )/ 1 )
=-0.824/( ( 0.236 + 0 )/ 1 )
=-0.824/0.236
=-349.15 %

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNBX Pharmaceuticals  (OTCPK:CNBX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


CNBX Pharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary